Cell death suppression increases efficacy of M2 vaccines
Significant public attention has recently been focused on the development of new anti-influenza (flu) vaccines that provide protection against a broad spectrum of viral strains. One proposed strategy is to utilize conserved viral protein, M2. Clinical trials of M2-containing influenza vaccines were recently initiated by US and European companies.